MX2007000783A - Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso. - Google Patents

Info

Publication number

MX2007000783A

MX2007000783A MX2007000783A MX2007000783A MX2007000783A MX 2007000783 A MX2007000783 A MX 2007000783A MX 2007000783 A MX2007000783 A MX 2007000783A MX 2007000783 A MX2007000783 A MX 2007000783A MX 2007000783 A MX2007000783 A MX 2007000783A

Authority

MX

Mexico

Prior art keywords

angptl4

antibody

cells

human

antibodies

Prior art date

2004-07-20

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 207
• 239000000203 mixture Substances 0.000 title claims abstract description 46
• 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 title claims description 20
• 102100025674 Angiopoietin-related protein 4 Human genes 0.000 title description 12
• 239000000556 agonist Substances 0.000 claims abstract description 80
• 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 claims abstract description 33
• 101150054149 ANGPTL4 gene Proteins 0.000 claims abstract description 20
• 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 claims abstract description 3
• 241000282414 Homo sapiens Species 0.000 claims description 116
• 239000005557 antagonist Substances 0.000 claims description 92
• 239000003795 chemical substances by application Substances 0.000 claims description 65
• 210000003494 hepatocyte Anatomy 0.000 claims description 50
• 230000035755 proliferation Effects 0.000 claims description 38
• 238000004519 manufacturing process Methods 0.000 claims description 35
• 101710085845 Angiopoietin-related protein 4 Proteins 0.000 claims description 34
• 150000007523 nucleic acids Chemical group 0.000 claims description 33
• 125000000539 amino acid group Chemical group 0.000 claims description 32
• 210000000229 preadipocyte Anatomy 0.000 claims description 30
• 150000001413 amino acids Chemical class 0.000 claims description 29
• 230000002401 inhibitory effect Effects 0.000 claims description 17
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
• 230000021164 cell adhesion Effects 0.000 claims description 16
• 230000004071 biological effect Effects 0.000 claims description 15
• 210000004899 c-terminal region Anatomy 0.000 claims description 15
• 238000006467 substitution reaction Methods 0.000 claims description 15
• 102000055659 human ANGPTL4 Human genes 0.000 claims description 13
• 230000004075 alteration Effects 0.000 claims description 6
• 230000006698 induction Effects 0.000 claims description 5
• 230000004936 stimulating effect Effects 0.000 claims description 5
• 108090000994 Catalytic RNA Proteins 0.000 claims description 4
• 102000053642 Catalytic RNA Human genes 0.000 claims description 4
• 230000000692 anti-sense effect Effects 0.000 claims description 4
• 230000001939 inductive effect Effects 0.000 claims description 4
• 108091092562 ribozyme Proteins 0.000 claims description 4
• 230000003472 neutralizing effect Effects 0.000 claims description 2
• 230000024245 cell differentiation Effects 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 108
• 238000011282 treatment Methods 0.000 abstract description 52
• 201000010099 disease Diseases 0.000 abstract description 49
• 230000012292 cell migration Effects 0.000 abstract description 11
• 230000004663 cell proliferation Effects 0.000 abstract description 7
• 238000003745 diagnosis Methods 0.000 abstract description 3
• 230000017455 cell-cell adhesion Effects 0.000 abstract 1
• 108090000623 proteins and genes Proteins 0.000 description 180
• 210000004027 cell Anatomy 0.000 description 173
• 108090000765 processed proteins & peptides Proteins 0.000 description 138
• 102000004196 processed proteins & peptides Human genes 0.000 description 127
• 229920001184 polypeptide Polymers 0.000 description 122
• 241001465754 Metazoa Species 0.000 description 88
• 235000018102 proteins Nutrition 0.000 description 71
• 102000004169 proteins and genes Human genes 0.000 description 71
• 230000027455 binding Effects 0.000 description 67
• 239000000427 antigen Substances 0.000 description 60
• 108091007433 antigens Proteins 0.000 description 58
• 102000036639 antigens Human genes 0.000 description 58
• 208000035475 disorder Diseases 0.000 description 57
• 239000003814 drug Substances 0.000 description 54
• 230000000694 effects Effects 0.000 description 54
• 239000012634 fragment Substances 0.000 description 54
• 230000014509 gene expression Effects 0.000 description 47
• 108020004414 DNA Proteins 0.000 description 45
• 125000003275 alpha amino acid group Chemical group 0.000 description 44
• -1 antisense molecules Proteins 0.000 description 42
• 230000009261 transgenic effect Effects 0.000 description 41
• 102000005962 receptors Human genes 0.000 description 38
• 108020003175 receptors Proteins 0.000 description 38
• 229940079593 drug Drugs 0.000 description 37
• 206010067125 Liver injury Diseases 0.000 description 36
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
• 210000004185 liver Anatomy 0.000 description 35
• 235000001014 amino acid Nutrition 0.000 description 32
• 150000002632 lipids Chemical class 0.000 description 32
• 210000002966 serum Anatomy 0.000 description 31
• 108060003951 Immunoglobulin Proteins 0.000 description 30
• 102000018358 immunoglobulin Human genes 0.000 description 30
• 206010028980 Neoplasm Diseases 0.000 description 29
• 208000008589 Obesity Diseases 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 28
• 102000039446 nucleic acids Human genes 0.000 description 28
• 108020004707 nucleic acids Proteins 0.000 description 28
• 235000020824 obesity Nutrition 0.000 description 28
• 239000013598 vector Substances 0.000 description 28
• 238000003556 assay Methods 0.000 description 27
• 150000001875 compounds Chemical class 0.000 description 26
• 231100000234 hepatic damage Toxicity 0.000 description 25
• 230000008818 liver damage Effects 0.000 description 25
• 230000006870 function Effects 0.000 description 24
• 238000001727 in vivo Methods 0.000 description 24
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
• 230000012010 growth Effects 0.000 description 23
• 102000004190 Enzymes Human genes 0.000 description 21
• 108090000790 Enzymes Proteins 0.000 description 21
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 21
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
• 229940088598 enzyme Drugs 0.000 description 21
• 238000012360 testing method Methods 0.000 description 21
• 210000001789 adipocyte Anatomy 0.000 description 20
• 230000002440 hepatic effect Effects 0.000 description 20
• 230000035772 mutation Effects 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 108010009906 Angiopoietins Proteins 0.000 description 19
• 102000009840 Angiopoietins Human genes 0.000 description 19
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 19
• 231100000334 hepatotoxic Toxicity 0.000 description 19
• 230000003082 hepatotoxic effect Effects 0.000 description 19
• 102000016267 Leptin Human genes 0.000 description 18
• 108010092277 Leptin Proteins 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 241000699670 Mus sp. Species 0.000 description 18
• 241000124008 Mammalia Species 0.000 description 17
• 210000000577 adipose tissue Anatomy 0.000 description 17
• 229940039781 leptin Drugs 0.000 description 17
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 17
• 230000004322 lipid homeostasis Effects 0.000 description 17
• 229940124597 therapeutic agent Drugs 0.000 description 17
• 238000006243 chemical reaction Methods 0.000 description 16
• 238000012986 modification Methods 0.000 description 16
• 239000000126 substance Substances 0.000 description 16
• 206010012601 diabetes mellitus Diseases 0.000 description 15
• 230000002159 abnormal effect Effects 0.000 description 14
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 14
• 239000012636 effector Substances 0.000 description 14
• 210000004408 hybridoma Anatomy 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 125000005647 linker group Chemical group 0.000 description 14
• 239000002502 liposome Substances 0.000 description 14
• 230000004048 modification Effects 0.000 description 14
• 150000003626 triacylglycerols Chemical class 0.000 description 14
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
• 230000007423 decrease Effects 0.000 description 13
• 239000003623 enhancer Substances 0.000 description 13
• 231100000753 hepatic injury Toxicity 0.000 description 13
• 230000001575 pathological effect Effects 0.000 description 13
• 102000004877 Insulin Human genes 0.000 description 12
• 108090001061 Insulin Proteins 0.000 description 12
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
• 230000001413 cellular effect Effects 0.000 description 12
• 235000012000 cholesterol Nutrition 0.000 description 12
• 230000002526 effect on cardiovascular system Effects 0.000 description 12
• 229940125396 insulin Drugs 0.000 description 12
• 239000002609 medium Substances 0.000 description 12
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 206010008635 Cholestasis Diseases 0.000 description 11
• 241001529936 Murinae Species 0.000 description 11
• 108010076504 Protein Sorting Signals Proteins 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 231100000359 cholestasis Toxicity 0.000 description 11
• 230000007870 cholestasis Effects 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 239000003925 fat Substances 0.000 description 11
• 235000019197 fats Nutrition 0.000 description 11
• 238000001415 gene therapy Methods 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 102000006495 integrins Human genes 0.000 description 11
• 108010044426 integrins Proteins 0.000 description 11
• 208000019423 liver disease Diseases 0.000 description 11
• 208000030159 metabolic disease Diseases 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 229940127089 cytotoxic agent Drugs 0.000 description 10
• 230000006378 damage Effects 0.000 description 10
• 239000013604 expression vector Substances 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 239000003112 inhibitor Substances 0.000 description 10
• 238000003780 insertion Methods 0.000 description 10
• 230000037431 insertion Effects 0.000 description 10
• 210000005229 liver cell Anatomy 0.000 description 10
• 239000003550 marker Substances 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 238000013518 transcription Methods 0.000 description 10
• 230000035897 transcription Effects 0.000 description 10
• 238000012546 transfer Methods 0.000 description 10
• 206010006895 Cachexia Diseases 0.000 description 9
• 241000588724 Escherichia coli Species 0.000 description 9
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 9
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 9
• 206010020772 Hypertension Diseases 0.000 description 9
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 9
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 9
• 230000002491 angiogenic effect Effects 0.000 description 9
• 239000002246 antineoplastic agent Substances 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 230000003511 endothelial effect Effects 0.000 description 9
• 239000008103 glucose Substances 0.000 description 9
• 229940088597 hormone Drugs 0.000 description 9
• 239000005556 hormone Substances 0.000 description 9
• 208000026278 immune system disease Diseases 0.000 description 9
• QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 8
• 201000001320 Atherosclerosis Diseases 0.000 description 8
• 208000024172 Cardiovascular disease Diseases 0.000 description 8
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 description 8
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 8
• 241000700605 Viruses Species 0.000 description 8
• 208000027418 Wounds and injury Diseases 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 230000033115 angiogenesis Effects 0.000 description 8
• 239000002870 angiogenesis inducing agent Substances 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 230000003013 cytotoxicity Effects 0.000 description 8
• 231100000135 cytotoxicity Toxicity 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 230000003902 lesion Effects 0.000 description 8
• 239000003446 ligand Substances 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 201000000050 myeloid neoplasm Diseases 0.000 description 8
• 210000000822 natural killer cell Anatomy 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 7
• 108010087819 Fc receptors Proteins 0.000 description 7
• 102000009109 Fc receptors Human genes 0.000 description 7
• 108010049003 Fibrinogen Proteins 0.000 description 7
• 102000008946 Fibrinogen Human genes 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 208000031226 Hyperlipidaemia Diseases 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000011759 adipose tissue development Effects 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 150000001720 carbohydrates Chemical class 0.000 description 7
• 108020001096 dihydrofolate reductase Proteins 0.000 description 7
• 238000006471 dimerization reaction Methods 0.000 description 7
• 210000002889 endothelial cell Anatomy 0.000 description 7
• 229940012952 fibrinogen Drugs 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 235000021588 free fatty acids Nutrition 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 210000005228 liver tissue Anatomy 0.000 description 7
• 210000001161 mammalian embryo Anatomy 0.000 description 7
• TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 7
• 239000003094 microcapsule Substances 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 239000003053 toxin Substances 0.000 description 7
• 229960004799 tryptophan Drugs 0.000 description 7
• 208000016261 weight loss Diseases 0.000 description 7
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
• 101710085848 Angiopoietin-related protein 3 Proteins 0.000 description 6
• 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
• 208000035150 Hypercholesterolemia Diseases 0.000 description 6
• 206010020751 Hypersensitivity Diseases 0.000 description 6
• 206010022489 Insulin Resistance Diseases 0.000 description 6
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
• QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
• 108700019146 Transgenes Proteins 0.000 description 6
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
• 230000005856 abnormality Effects 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 231100000433 cytotoxic Toxicity 0.000 description 6
• 230000001472 cytotoxic effect Effects 0.000 description 6
• 230000008030 elimination Effects 0.000 description 6
• 238000003379 elimination reaction Methods 0.000 description 6
• 210000001671 embryonic stem cell Anatomy 0.000 description 6
• 230000002255 enzymatic effect Effects 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 208000006454 hepatitis Diseases 0.000 description 6
• 231100000283 hepatitis Toxicity 0.000 description 6
• 238000002744 homologous recombination Methods 0.000 description 6
• 230000006801 homologous recombination Effects 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
• 230000001900 immune effect Effects 0.000 description 6
• 229940127121 immunoconjugate Drugs 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 6
• 210000004738 parenchymal cell Anatomy 0.000 description 6
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 230000002285 radioactive effect Effects 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 231100000765 toxin Toxicity 0.000 description 6
• 108700012359 toxins Proteins 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 230000004580 weight loss Effects 0.000 description 6
• 208000030507 AIDS Diseases 0.000 description 5
• 108010088751 Albumins Proteins 0.000 description 5
• 102000009027 Albumins Human genes 0.000 description 5
• 239000004475 Arginine Substances 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 206010064571 Gene mutation Diseases 0.000 description 5
• 206010019280 Heart failures Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• 108010013563 Lipoprotein Lipase Proteins 0.000 description 5
• 102100022119 Lipoprotein lipase Human genes 0.000 description 5
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
• 229930193140 Neomycin Natural products 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• 102000012753 TIE-2 Receptor Human genes 0.000 description 5
• 108010090091 TIE-2 Receptor Proteins 0.000 description 5
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
• 230000002494 anti-cea effect Effects 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 5
• 229960002170 azathioprine Drugs 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000001588 bifunctional effect Effects 0.000 description 5
• 229930195731 calicheamicin Natural products 0.000 description 5
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 230000004087 circulation Effects 0.000 description 5
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
• 208000029078 coronary artery disease Diseases 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 230000002503 metabolic effect Effects 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 230000003278 mimic effect Effects 0.000 description 5
• 239000002105 nanoparticle Substances 0.000 description 5
• 229960004927 neomycin Drugs 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 150000003431 steroids Chemical class 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 230000006820 DNA synthesis Effects 0.000 description 4
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 208000032928 Dyslipidaemia Diseases 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 206010019851 Hepatotoxicity Diseases 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 206010020880 Hypertrophy Diseases 0.000 description 4
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 4
• 241000235649 Kluyveromyces Species 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• 208000017170 Lipid metabolism disease Diseases 0.000 description 4
• 102000004895 Lipoproteins Human genes 0.000 description 4
• 108090001030 Lipoproteins Proteins 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 108090000157 Metallothionein Proteins 0.000 description 4
• 101000693095 Mus musculus Angiopoietin-related protein 4 Proteins 0.000 description 4
• 206010028851 Necrosis Diseases 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 208000006011 Stroke Diseases 0.000 description 4
• 208000012346 Venoocclusive disease Diseases 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 230000009824 affinity maturation Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 239000002254 cytotoxic agent Substances 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• 208000007386 hepatic encephalopathy Diseases 0.000 description 4
• 231100000304 hepatotoxicity Toxicity 0.000 description 4
• 230000007686 hepatotoxicity Effects 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000002779 inactivation Effects 0.000 description 4
• 238000010348 incorporation Methods 0.000 description 4
• 210000003292 kidney cell Anatomy 0.000 description 4
• 208000017169 kidney disease Diseases 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
• 229960003105 metformin Drugs 0.000 description 4
• 239000004005 microsphere Substances 0.000 description 4
• 230000005012 migration Effects 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 235000015097 nutrients Nutrition 0.000 description 4
• 230000000771 oncological effect Effects 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• 239000013603 viral vector Substances 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 3
• 102100033402 Angiopoietin-4 Human genes 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
• 201000004569 Blindness Diseases 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 208000017667 Chronic Disease Diseases 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
• 208000016192 Demyelinating disease Diseases 0.000 description 3
• 206010012305 Demyelination Diseases 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 101800003838 Epidermal growth factor Proteins 0.000 description 3
• 102400001368 Epidermal growth factor Human genes 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
• 108010051696 Growth Hormone Proteins 0.000 description 3
• 206010020710 Hyperphagia Diseases 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 241001138401 Kluyveromyces lactis Species 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• 108010007622 LDL Lipoproteins Proteins 0.000 description 3
• 102000007330 LDL Lipoproteins Human genes 0.000 description 3
• 102000003792 Metallothionein Human genes 0.000 description 3
• 229930192392 Mitomycin Natural products 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• 241000700584 Simplexvirus Species 0.000 description 3
• 102100038803 Somatotropin Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 108090000340 Transaminases Proteins 0.000 description 3
• 102000003929 Transaminases Human genes 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• 108010031318 Vitronectin Proteins 0.000 description 3
• 102100035140 Vitronectin Human genes 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 239000003263 anabolic agent Substances 0.000 description 3
• 229940070021 anabolic steroids Drugs 0.000 description 3
• 108010069801 angiopoietin 4 Proteins 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 239000002830 appetite depressant Substances 0.000 description 3
• 125000003118 aryl group Chemical group 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 210000000941 bile Anatomy 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 230000031018 biological processes and functions Effects 0.000 description 3
• 230000017531 blood circulation Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 235000019577 caloric intake Nutrition 0.000 description 3
• 150000001718 carbodiimides Chemical class 0.000 description 3
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 3
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
• 229960001076 chlorpromazine Drugs 0.000 description 3
• 201000001883 cholelithiasis Diseases 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 238000011260 co-administration Methods 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 239000003433 contraceptive agent Substances 0.000 description 3
• 230000002254 contraceptive effect Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 206010061428 decreased appetite Diseases 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 125000002228 disulfide group Chemical group 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 229940116977 epidermal growth factor Drugs 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 239000000122 growth hormone Substances 0.000 description 3
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
• 229960003132 halothane Drugs 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 230000002390 hyperplastic effect Effects 0.000 description 3
• 230000001969 hypertrophic effect Effects 0.000 description 3
• 150000002463 imidates Chemical class 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
• 229960004657 indocyanine green Drugs 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 229940100601 interleukin-6 Drugs 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 108010019813 leptin receptors Proteins 0.000 description 3
• 230000037356 lipid metabolism Effects 0.000 description 3
• 229960001428 mercaptopurine Drugs 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 239000002088 nanocapsule Substances 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 238000012753 partial hepatectomy Methods 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
• 229920001451 polypropylene glycol Polymers 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000033458 reproduction Effects 0.000 description 3
• 239000011347 resin Substances 0.000 description 3
• 229920005989 resin Polymers 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 208000001076 sarcopenia Diseases 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 238000012385 systemic delivery Methods 0.000 description 3
• 229960001603 tamoxifen Drugs 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• 235000019155 vitamin A Nutrition 0.000 description 3
• 239000011719 vitamin A Substances 0.000 description 3
• 229940045997 vitamin a Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
• GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 2
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
• IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
• YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 2
• XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
• VTBWEIQIRVBELM-UHFFFAOYSA-P 4-[2-[(4-diazoniobenzoyl)amino]ethylcarbamoyl]benzenediazonium Chemical compound [N+](#N)C1=CC=C(C(=O)NCCNC(C2=CC=C(C=C2)[N+]#N)=O)C=C1 VTBWEIQIRVBELM-UHFFFAOYSA-P 0.000 description 2
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 108010051457 Acid Phosphatase Proteins 0.000 description 2
• 102000013563 Acid Phosphatase Human genes 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
• 101710083889 Alpha-fetoprotein Proteins 0.000 description 2
• 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 2
• 108010048154 Angiopoietin-1 Proteins 0.000 description 2
• 102000009088 Angiopoietin-1 Human genes 0.000 description 2
• 102100034608 Angiopoietin-2 Human genes 0.000 description 2
• 108010048036 Angiopoietin-2 Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 241000194108 Bacillus licheniformis Species 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 241000255789 Bombyx mori Species 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 102100031168 CCN family member 2 Human genes 0.000 description 2
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 101800001982 Cholecystokinin Proteins 0.000 description 2
• 102100025841 Cholecystokinin Human genes 0.000 description 2
• 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
• 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
• 102000003914 Cholinesterases Human genes 0.000 description 2
• 108090000322 Cholinesterases Proteins 0.000 description 2
• 206010010075 Coma hepatic Diseases 0.000 description 2
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
• 102000004420 Creatine Kinase Human genes 0.000 description 2
• 108010042126 Creatine kinase Proteins 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
• 108050006400 Cyclin Proteins 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 108010053770 Deoxyribonucleases Proteins 0.000 description 2
• 102000016911 Deoxyribonucleases Human genes 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 241000255925 Diptera Species 0.000 description 2
• 241001379910 Ephemera danica Species 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
• 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
• 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 206010019663 Hepatic failure Diseases 0.000 description 2
• 208000009889 Herpes Simplex Diseases 0.000 description 2
• 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 206010021024 Hypolipidaemia Diseases 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102400001355 Interleukin-8 Human genes 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
• 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
• 244000285963 Kluyveromyces fragilis Species 0.000 description 2
• 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 102100031775 Leptin receptor Human genes 0.000 description 2
• 239000004907 Macro-emulsion Substances 0.000 description 2
• 101710151321 Melanostatin Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 102400000064 Neuropeptide Y Human genes 0.000 description 2
• 108090000742 Neurotrophin 3 Proteins 0.000 description 2
• 102100029268 Neurotrophin-3 Human genes 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
• 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
• 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 241000237988 Patellidae Species 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 208000004880 Polyuria Diseases 0.000 description 2
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
• 101710119301 Protein delta homolog 1 Proteins 0.000 description 2
• 102100027378 Prothrombin Human genes 0.000 description 2
• 108010094028 Prothrombin Proteins 0.000 description 2
• 108091008103 RNA aptamers Proteins 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 241000607720 Serratia Species 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
• 241000256251 Spodoptera frugiperda Species 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical class [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 208000001435 Thromboembolism Diseases 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 206010054094 Tumour necrosis Diseases 0.000 description 2
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 206010046996 Varicose vein Diseases 0.000 description 2
• 206010047097 Vascular purpura Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 206010047249 Venous thrombosis Diseases 0.000 description 2
• 206010058874 Viraemia Diseases 0.000 description 2
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 201000010272 acanthosis nigricans Diseases 0.000 description 2
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 239000000808 adrenergic beta-agonist Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000001476 alcoholic effect Effects 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960004909 aminosalicylic acid Drugs 0.000 description 2
• 230000001548 androgenic effect Effects 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 230000003527 anti-angiogenesis Effects 0.000 description 2
• 230000003432 anti-folate effect Effects 0.000 description 2
• 239000003472 antidiabetic agent Substances 0.000 description 2
• 229940127074 antifolate Drugs 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 229910052785 arsenic Inorganic materials 0.000 description 2
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 108010014210 axokine Proteins 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 description 2
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
• 210000000013 bile duct Anatomy 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 238000010876 biochemical test Methods 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000001045 blue dye Substances 0.000 description 2
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 210000001736 capillary Anatomy 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 229960004782 chlordiazepoxide Drugs 0.000 description 2
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
• 229940107137 cholecystokinin Drugs 0.000 description 2
• 229940048961 cholinesterase Drugs 0.000 description 2
• 208000020832 chronic kidney disease Diseases 0.000 description 2
• 230000001886 ciliary effect Effects 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 229960001214 clofibrate Drugs 0.000 description 2
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
• 238000005354 coacervation Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
• KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
• 229960004890 diethylpropion Drugs 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 125000005442 diisocyanate group Chemical group 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• 150000004662 dithiols Chemical class 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 230000009843 endothelial lesion Effects 0.000 description 2
• 230000019439 energy homeostasis Effects 0.000 description 2
• AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 2
• 229960003203 erythromycin estolate Drugs 0.000 description 2
• JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
• 239000005038 ethylene vinyl acetate Substances 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 235000013861 fat-free Nutrition 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 150000002222 fluorine compounds Chemical class 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 235000012631 food intake Nutrition 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 102000018146 globin Human genes 0.000 description 2
• 108060003196 globin Proteins 0.000 description 2
• 230000004153 glucose metabolism Effects 0.000 description 2
• 238000007446 glucose tolerance test Methods 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
• 201000001059 hepatic coma Diseases 0.000 description 2
• 206010019692 hepatic necrosis Diseases 0.000 description 2
• 230000007866 hepatic necrosis Effects 0.000 description 2
• 210000004024 hepatic stellate cell Anatomy 0.000 description 2
• 208000005252 hepatitis A Diseases 0.000 description 2
• 235000009200 high fat diet Nutrition 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• 208000006575 hypertriglyceridemia Diseases 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000008676 import Effects 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 108091008042 inhibitory receptors Proteins 0.000 description 2
• 229940096397 interleukin-8 Drugs 0.000 description 2
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
• 102000010681 interleukin-8 receptors Human genes 0.000 description 2
• 108010038415 interleukin-8 receptors Proteins 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
• 238000011542 limb amputation Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
• 238000012317 liver biopsy Methods 0.000 description 2
• 208000007903 liver failure Diseases 0.000 description 2
• 231100000835 liver failure Toxicity 0.000 description 2
• 230000003908 liver function Effects 0.000 description 2
• 238000007449 liver function test Methods 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000013011 mating Effects 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000006371 metabolic abnormality Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 229960001566 methyltestosterone Drugs 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 239000002858 neurotransmitter agent Substances 0.000 description 2
• 229940032018 neurotrophin 3 Drugs 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 229940127234 oral contraceptive Drugs 0.000 description 2
• 239000003539 oral contraceptive agent Substances 0.000 description 2
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
• 229960003104 ornithine Drugs 0.000 description 2
• 230000000399 orthopedic effect Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 210000001322 periplasm Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 229960000436 phendimetrazine Drugs 0.000 description 2
• 229960003562 phentermine Drugs 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
• 229960002036 phenytoin Drugs 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 206010036067 polydipsia Diseases 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 229960002965 pravastatin Drugs 0.000 description 2
• TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 229960002662 propylthiouracil Drugs 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 229940039716 prothrombin Drugs 0.000 description 2
• 230000005180 public health Effects 0.000 description 2
• ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 2
• 229930002356 pyrrolizidine alkaloid Natural products 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000002708 random mutagenesis Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 229930002330 retinoic acid Natural products 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 229960002073 sertraline Drugs 0.000 description 2
• IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 230000035924 thermogenesis Effects 0.000 description 2
• 125000000101 thioether group Chemical group 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
• ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 2
• 231100000607 toxicokinetics Toxicity 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• 235000013619 trace mineral Nutrition 0.000 description 2
• 239000011573 trace mineral Substances 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 101150108727 trpl gene Proteins 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
• 229960000604 valproic acid Drugs 0.000 description 2
• 208000027185 varicose disease Diseases 0.000 description 2
• 210000000264 venule Anatomy 0.000 description 2
• BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
• 229960000317 yohimbine Drugs 0.000 description 2
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
• WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
• JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
• OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 description 1
• FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
• ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
• QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
• LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
• 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
• GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical class OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
• 208000021959 Abnormal metabolism Diseases 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 208000032484 Accidental exposure to product Diseases 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• 241000256118 Aedes aegypti Species 0.000 description 1
• 241000256173 Aedes albopictus Species 0.000 description 1
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
• 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
• 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
• 241000545417 Aleurites Species 0.000 description 1
• 102100034033 Alpha-adducin Human genes 0.000 description 1
• RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
• 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
• 102000004452 Arginase Human genes 0.000 description 1
• 108700024123 Arginases Proteins 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 206010051113 Arterial restenosis Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000713842 Avian sarcoma virus Species 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 208000004597 Bacillary angiomatosis Diseases 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
• 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
• 108010081589 Becaplermin Proteins 0.000 description 1
• 206010004269 Benign hepatic neoplasm Diseases 0.000 description 1
• 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 108090000489 Carboxy-Lyases Proteins 0.000 description 1
• 102000004031 Carboxy-Lyases Human genes 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 108091060290 Chromatid Proteins 0.000 description 1
• 108010004103 Chylomicrons Proteins 0.000 description 1
• 108090000746 Chymosin Proteins 0.000 description 1
• 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 229920002911 Colestipol Polymers 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 102400000739 Corticotropin Human genes 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 241001219085 Cyclopia Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012441 Dermatitis bullous Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000012239 Developmental disease Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 101710146739 Enterotoxin Proteins 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588698 Erwinia Species 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 241001522878 Escherichia coli B Species 0.000 description 1
• 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 208000004332 Evans syndrome Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
• 108010011459 Exenatide Proteins 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 101710082714 Exotoxin A Proteins 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 108010003471 Fetal Proteins Proteins 0.000 description 1
• 102000004641 Fetal Proteins Human genes 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
• 201000001498 Froelich syndrome Diseases 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 201000005618 Glomus Tumor Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 102000030595 Glucokinase Human genes 0.000 description 1
• 108010021582 Glucokinase Proteins 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 244000299507 Gossypium hirsutum Species 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 108010012029 Guanine Deaminase Proteins 0.000 description 1
• 102000013587 Guanine deaminase Human genes 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 208000002125 Hemangioendothelioma Diseases 0.000 description 1
• 208000006050 Hemangiopericytoma Diseases 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
• 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 208000037319 Hepatitis infectious Diseases 0.000 description 1
• 206010019837 Hepatocellular injury Diseases 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 208000023817 Hepatoportal sclerosis Diseases 0.000 description 1
• 102000005548 Hexokinase Human genes 0.000 description 1
• 108700040460 Hexokinases Proteins 0.000 description 1
• 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 1
• 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
• 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000852214 Homo sapiens THO complex subunit 4 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
• 206010049645 Hypercatabolism Diseases 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 206010020674 Hypermetabolism Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
• 206010021067 Hypopituitarism Diseases 0.000 description 1
• 206010021128 Hypotriglyceridaemia Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102100022339 Integrin alpha-L Human genes 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 241000481961 Lachancea thermotolerans Species 0.000 description 1
• 241000235651 Lachancea waltii Species 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
• 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 229940127470 Lipase Inhibitors Drugs 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 208000018501 Lymphatic disease Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 206010025282 Lymphoedema Diseases 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 229930126263 Maytansine Natural products 0.000 description 1
• 241001441512 Maytenus serrata Species 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 241000221961 Neurospora crassa Species 0.000 description 1
• 101100324450 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arp-4 gene Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 208000014060 Niemann-Pick disease Diseases 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 102000001490 Opioid Peptides Human genes 0.000 description 1
• 108010093625 Opioid Peptides Proteins 0.000 description 1
• 102000016978 Orphan receptors Human genes 0.000 description 1
• 108070000031 Orphan receptors Proteins 0.000 description 1
• 101100081884 Oryza sativa subsp. japonica OSA15 gene Proteins 0.000 description 1
• 206010033307 Overweight Diseases 0.000 description 1
• 101150014691 PPARA gene Proteins 0.000 description 1
• 101150082245 PSAG gene Proteins 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 241000228143 Penicillium Species 0.000 description 1
• 108090000279 Peptidyltransferases Proteins 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 240000007377 Petunia x hybrida Species 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
• 102000001105 Phosphofructokinases Human genes 0.000 description 1
• 108010069341 Phosphofructokinases Proteins 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 108091036407 Polyadenylation Proteins 0.000 description 1
• 229920000805 Polyaspartic acid Polymers 0.000 description 1
• 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• 102100024819 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100036467 Protein delta homolog 1 Human genes 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
• 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
• 102000013009 Pyruvate Kinase Human genes 0.000 description 1
• 108020005115 Pyruvate Kinase Proteins 0.000 description 1
• 102000004879 Racemases and epimerases Human genes 0.000 description 1
• 108090001066 Racemases and epimerases Proteins 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 240000003946 Saponaria officinalis Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 241000311088 Schwanniomyces Species 0.000 description 1
• 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
• 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 208000004732 Systemic Vasculitis Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 241000255588 Tephritidae Species 0.000 description 1
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 241001149964 Tolypocladium Species 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 241000223259 Trichoderma Species 0.000 description 1
• 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
• 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
• 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 241000235013 Yarrowia Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
• PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 1
• UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 231100000818 accidental exposure Toxicity 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 210000003486 adipose tissue brown Anatomy 0.000 description 1
• 210000000593 adipose tissue white Anatomy 0.000 description 1
• 239000000464 adrenergic agent Substances 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000007818 agglutination assay Methods 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 229940050528 albumin Drugs 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
• 229960003459 allopurinol Drugs 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 125000000337 alpha-glutamyl group Chemical group 0.000 description 1
• CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
• 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
• 229960000212 aminophenazone Drugs 0.000 description 1
• FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
• 229960003556 aminophylline Drugs 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
• 229960002105 amrinone Drugs 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 229940035674 anesthetics Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000001539 anorectic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003602 anti-herpes Effects 0.000 description 1
• 230000036436 anti-hiv Effects 0.000 description 1
• 230000003388 anti-hormonal effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 230000009876 antimalignant effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
• 208000010927 atrophic thyroiditis Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229950003745 benzfetamine Drugs 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 238000005460 biophysical method Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229940046049 bontril Drugs 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 230000004706 cardiovascular dysfunction Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 150000003943 catecholamines Chemical class 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 235000019994 cava Nutrition 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
• 229950002397 cetilistat Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
• 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
• 229940106681 chloroacetic acid Drugs 0.000 description 1
• TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
• 229960003633 chlorzoxazone Drugs 0.000 description 1
• 230000001587 cholestatic effect Effects 0.000 description 1
• 230000031154 cholesterol homeostasis Effects 0.000 description 1
• 235000020974 cholesterol intake Nutrition 0.000 description 1
• 239000000064 cholinergic agonist Substances 0.000 description 1
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
• 210000004756 chromatid Anatomy 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229940080701 chymosin Drugs 0.000 description 1
• 229960001380 cimetidine Drugs 0.000 description 1
• CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229960002227 clindamycin Drugs 0.000 description 1
• KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 229960002604 colestipol Drugs 0.000 description 1
• GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
• 229960000766 danazol Drugs 0.000 description 1
• 229960001987 dantrolene Drugs 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• 239000012954 diazonium Substances 0.000 description 1
• 229960004042 diazoxide Drugs 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000018823 dietary intake Nutrition 0.000 description 1
• 235000001434 dietary modification Nutrition 0.000 description 1
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
• ICFXZZFWRWNZMA-UHFFFAOYSA-N diethylpropion hydrochloride Chemical compound [Cl-].CC[NH+](CC)C(C)C(=O)C1=CC=CC=C1 ICFXZZFWRWNZMA-UHFFFAOYSA-N 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 229960004166 diltiazem Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
• 229960001066 disopyramide Drugs 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 229960002563 disulfiram Drugs 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000008497 endothelial barrier function Effects 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
• 229960000305 enflurane Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• 108060002566 ephrin Proteins 0.000 description 1
• 102000012803 ephrin Human genes 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 229960001519 exenatide Drugs 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 208000009866 extrahepatic cholestasis Diseases 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 229940054572 ezetimibe / simvastatin Drugs 0.000 description 1
• 201000005577 familial hyperlipidemia Diseases 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• DLEGDLSLRSOURQ-UHFFFAOYSA-N fluroxene Chemical compound FC(F)(F)COC=C DLEGDLSLRSOURQ-UHFFFAOYSA-N 0.000 description 1
• 229950010045 fluroxene Drugs 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000012817 gel-diffusion technique Methods 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 229940112611 glucovance Drugs 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
• DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
• 229960002867 griseofulvin Drugs 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000001553 hepatotropic effect Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 102000048638 human UQCRH Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 229940014041 hyaluronate Drugs 0.000 description 1
• 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
• 201000010930 hyperostosis Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 229940126904 hypoglycaemic agent Drugs 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 208000026621 hypolipoproteinemia Diseases 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 230000035851 hypotriglyceridemia Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 201000006334 interstitial nephritis Diseases 0.000 description 1
• 230000031891 intestinal absorption Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 102000005861 leptin receptors Human genes 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 230000013190 lipid storage Effects 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• 230000003520 lipogenic effect Effects 0.000 description 1
• 235000019136 lipoic acid Nutrition 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 230000008604 lipoprotein metabolism Effects 0.000 description 1
• 230000005817 liver abnormality Effects 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229960003566 lomitapide Drugs 0.000 description 1
• QKVKOFVWUHNEBX-UHFFFAOYSA-N lomitapide mesylate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 QKVKOFVWUHNEBX-UHFFFAOYSA-N 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 206010025226 lymphangitis Diseases 0.000 description 1
• 208000018555 lymphatic system disease Diseases 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 208000002502 lymphedema Diseases 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 229960003439 mebendazole Drugs 0.000 description 1
• BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 229940045623 meridia Drugs 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 208000011661 metabolic syndrome X Diseases 0.000 description 1
• RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 description 1
• PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
• RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
• 229960002455 methoxyflurane Drugs 0.000 description 1
• RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• 229960003404 mexiletine Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000003228 microsomal effect Effects 0.000 description 1
• 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
• 229960004127 naloxone Drugs 0.000 description 1
• 229960003086 naltrexone Drugs 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 230000001293 nucleolytic effect Effects 0.000 description 1
• 235000006180 nutrition needs Nutrition 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 239000003399 opiate peptide Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002891 organic anions Chemical class 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
• 229960001019 oxacillin Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
• YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229960001789 papaverine Drugs 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 229960000762 perphenazine Drugs 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
• 229960003243 phenformin Drugs 0.000 description 1
• 229960003209 phenmetrazine Drugs 0.000 description 1
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
• 229960002695 phenobarbital Drugs 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 101150009573 phoA gene Proteins 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000004713 phosphodiesters Chemical group 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 210000005059 placental tissue Anatomy 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920000867 polyelectrolyte Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000005373 porous glass Substances 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 229960003611 pramlintide Drugs 0.000 description 1
• 108010029667 pramlintide Proteins 0.000 description 1
• NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
• 229940063238 premarin Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 230000001023 pro-angiogenic effect Effects 0.000 description 1
• 229960000244 procainamide Drugs 0.000 description 1
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229960003598 promazine Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
• 230000001012 protector Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000001107 psychogenic effect Effects 0.000 description 1
• 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
• 229960002290 pyridostigmine Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
• 229960000620 ranitidine Drugs 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000006884 regulation of angiogenesis Effects 0.000 description 1
• 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000020874 response to hypoxia Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 229940110294 revia Drugs 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 229960004796 rosuvastatin calcium Drugs 0.000 description 1
• XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 230000005586 smoking cessation Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• 229960001734 sulfobromophthalein Drugs 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 229940034887 tenuate Drugs 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 230000000476 thermogenic effect Effects 0.000 description 1
• WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
• 235000010296 thiabendazole Nutrition 0.000 description 1
• 239000004308 thiabendazole Substances 0.000 description 1
• 229960004546 thiabendazole Drugs 0.000 description 1
• 229960002178 thiamazole Drugs 0.000 description 1
• 229960002663 thioctic acid Drugs 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000005060 thrombophlebitis Diseases 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 230000024033 toxin binding Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 238000012384 transportation and delivery Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229930013292 trichothecene Natural products 0.000 description 1
• 150000003327 trichothecene derivatives Chemical class 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 208000014902 triglyceride storage disease Diseases 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• 108010087967 type I signal peptidase Proteins 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 229960005088 urethane Drugs 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 231100000216 vascular lesion Toxicity 0.000 description 1
• 206010055031 vascular neoplasm Diseases 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 208000037997 venous disease Diseases 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
• 239000013585 weight reducing agent Substances 0.000 description 1
• 229940009065 wellbutrin Drugs 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 229940002552 xenical Drugs 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1
• 230000002034 xenobiotic effect Effects 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1
• 229950006967 zoxazolamine Drugs 0.000 description 1